Centre d'Immunologie de Marseille-Luminy-CIML, Aix-Marseille Université UM2, Marseille, France.
PLoS One. 2012;7(11):e49419. doi: 10.1371/journal.pone.0049419. Epub 2012 Nov 16.
We compared gene expression signatures of aggressive amelanotic (Amela) melanomas with those of slowly growing pigmented melanomas (Mela), identifying pathways potentially responsible for the aggressive Amela phenotype. Both tumors develop in mice upon conditional deletion in melanocytes of Ink4a/Arf tumor suppressor genes with concomitant expression of oncogene H-Ras(G12V) and a known tumor antigen. We previously showed that only the aggressive Amela tumors were highly infiltrated by leukocytes concomitant with local and systemic inflammation. We report that Amela tumors present a pattern of de-differentiation with reduced expression of genes involved in pigmentation. This correlates with reduced and enhanced expression, respectively, of microphthalmia-associated (Mitf) and Pou3f2/Brn-2 transcription factors. The reduced expression of Mitf-controlled melanocyte differentiation antigens also observed in some human cutaneous melanoma has important implications for immunotherapy protocols that generally target such antigens. Induced Amela tumors also express Epithelial-Mesenchymal-Transition (EMT)-like and TGFβ-pathway signatures. These are correlated with constitutive Smad3 signaling in Amela tumors and melanoma cell lines. Signatures of infiltrating leukocytes and some chemokines such as chemotactic cytokine ligand 2 (Ccl2) that contribute to leukocyte recruitment further characterize Amela tumors. Inhibition of the mitogen-activated protein kinase (MAPK) activation pathway in Amela tumor lines leads to reduced expression of EMT hallmark genes and inhibits both proinflammatory cytokine Ccl2 gene expression and Ccl2 production by the melanoma cells. These results indicate a link between EMT-like processes and alterations of immune functions, both being controlled by the MAPK pathway. They further suggest that targeting the MAPK pathway within tumor cells will impact tumor-intrinsic oncogenic properties as well as the nature of the tumor microenvironment.
我们比较了侵袭性无黑色素(Amela)黑色素瘤和生长缓慢的色素性黑色素瘤(Mela)的基因表达特征,确定了可能导致侵袭性 Amela 表型的潜在途径。这两种肿瘤都是在黑素细胞中条件性缺失 Ink4a/Arf 肿瘤抑制基因,同时表达致癌基因 H-Ras(G12V)和一种已知的肿瘤抗原后,在小鼠中发展起来的。我们之前曾表明,只有侵袭性 Amela 肿瘤才会被白细胞高度浸润,同时伴有局部和全身炎症。我们报告称,Amela 肿瘤呈现出去分化模式,参与色素形成的基因表达减少。这与小眼畸形相关转录因子(Mitf)和 Pou3f2/Brn-2 转录因子的表达分别减少和增强相对应。在一些人类皮肤黑色素瘤中观察到的受 Mitf 控制的黑色素细胞分化抗原表达减少,这对通常针对这些抗原的免疫治疗方案具有重要意义。诱导的 Amela 肿瘤也表达上皮-间充质转化(EMT)样和 TGFβ 通路特征。这些与 Amela 肿瘤和黑色素瘤细胞系中组成性 Smad3 信号传导相关。浸润性白细胞的特征和一些趋化因子,如趋化因子配体 2(Ccl2),有助于白细胞募集,进一步描述了 Amela 肿瘤。在 Amela 肿瘤系中抑制丝裂原活化蛋白激酶(MAPK)激活途径会导致 EMT 特征基因的表达减少,并抑制促炎细胞因子 Ccl2 基因的表达和黑色素瘤细胞产生 Ccl2。这些结果表明 EMT 样过程与免疫功能的改变之间存在联系,这两者均受 MAPK 途径控制。它们进一步表明,针对肿瘤细胞内的 MAPK 途径将影响肿瘤内在的致癌特性以及肿瘤微环境的性质。